|
17 Jan 2022 |
Jacobio Receives IND Approval for Aurora A Inhibitor JAB-2485 from FDA
|
|
17 Jan 2022 |
U.S. FDA Approves Pfizer’s CIBINQO® (abrocitinib) for Adults with Moderate-to-Severe Atopic Dermatitis
|
|
17 Jan 2022 |
U.S. FDA Approves RINVOQ® (upadacitinib) to Treat Adults and Children 12 Years and Older with Refractory, Moderate to Severe Atopic Dermatitis
|
|
13 Jan 2022 |
Salarius Pharmaceuticals Expands Oncology Pipeline Through Strategic Acquisition of Targeted Protein Degradation Portfolio from DeuteRx, LLC
|
|
13 Jan 2022 |
BridgeBio Announces Clinical Collaboration with Amgen to Study BBP-398, a Potentially Best-in-class SHP2 Inhibitor, in Combination with LUMAKRAS® (sotorasib) in Advanced Solid Tumors with the KRAS G12C Mutation
|
|
13 Jan 2022 |
Captor Therapeutics Presents Compelling In Vivo Proof-of-Concept Data from CT-01 Program in Hepatocellular Carcinoma
|
|
13 Jan 2022 |
AI Therapeutics Announces Initiation of a Phase II Clinical Trial of AIT-101 for Treatment of ALS
|
|
13 Jan 2022 |
SK life science Announces FDA Clearance of IND Application for its Oncology Candidate, SKL27969, a PRMT5 Inhibitor for the Potential Treatment of Advanced Solid Tumors
|
|
11 Jan 2022 |
European Commission Approves KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat Children With Cystic Fibrosis Ages 6 to 11 Years
|
|
11 Jan 2022 |
Amgen and Arrakis Therapeutics announce multi-target collaboration to identify novel RNA degrader small molecule therapeutics
|
|
10 Jan 2022 |
Idorsia receives US FDA approval of QUVIVIQ (daridorexant) 25 and 50 mg for the treatment of adults with insomnia
|
|
10 Jan 2022 |
Nurix Therapeutics Advances Clinical and Preclinical Pipeline and Outlines 2022 Catalysts
|
|
10 Jan 2022 |
SIGA Technologies Receives Approval from the European Medicines Agency for Tecovirimat
|
|
10 Jan 2022 |
Viking Therapeutics Announces Initiation of Phase 1 Clinical Trial of VK2735, Company's Lead Dual GLP-1/GIP Receptor Agonist
|
|
10 Jan 2022 |
European Commission approves Lumykras® (sotorasib) for patients with KRAS G12C-mutated advanced non-small cell lung cancer
|
|
08 Jan 2022 |
BioCryst Begins Patient Enrollment in REDEEM-1 Pivotal Trial Evaluating BCX9930 as Oral Monotherapy for Patients with PNH
|
|
08 Jan 2022 |
AbbVie Submits Applications for Upadacitinib (RINVOQ®) in Non-Radiographic Axial Spondyloarthritis to U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA)
|
|
07 Jan 2022 |
Nuvalent Announces First Patient Dosed in ARROS-1 Phase 1/2 Clinical Trial of NVL-520, its Novel ROS1-selective Inhibitor
|
|
07 Jan 2022 |
Adlai Nortye Announces First Patient Dosed in Phase I Clinical Trial of the orally available, small-molecule PD-L1 inhibitor AN4005 for Advanced Tumors
|
|
07 Jan 2022 |
Edgewise Therapeutics Announces Positive Topline Results From the EDG-5506 Phase 1b Clinical Trial in Adults With Becker Muscular Dystrophy (BMD)
|
|
07 Jan 2022 |
Clear Creek Bio Advances Its Highly Potent SARS-CoV-2 PLpro Inhibitors in Discovery of an Oral Direct-Acting Antiviral to Treat COVID-19
|
|
05 Jan 2022 |
Rain Therapeutics and Roche to Collaborate on Clinical Trial of Milademetan Combination with Anti-PD-L1 Immunotherapy for Various Solid Tumor Indications
|
|
05 Jan 2022 |
Relay Therapeutics Announces Dosing of First Patient in First-in-Human Trial of RLY-2608 and Initiation of Expansion Cohorts for First-In-Human Trial of RLY-4008
|
|
05 Jan 2022 |
Amylyx Pharmaceuticals Submits Marketing Authorization Application (MAA) for AMX0035 for the Treatment of ALS
|
|
05 Jan 2022 |
NewAmsterdam Pharma Doses First Patient in Phase 3 BROADWAY Trial of Obicetrapib in Adults with Heterozygous Familial Hypercholesterolemia (HeFH) and/or Established Atherosclerotic Cardiovascular Disease (ASCVD)
|
